title: ETUDE DE LA PHARMACOCINETIQUE  DE L’ASSOCIATION PIPERACILLINE – TAZOBACTAM EN UTILISATION INTRA-VEINEUSE CONTINUE CHEZ L’ENFANT NEUTROPENIQUE FEBRILE .

lead_sponsor: CHRU de Lille


title: Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I”

acronym: FOGG-I

source: euctr

lead_sponsor: Chru de Lille

study_type: Interventional

status: Completed

lead_sponsor_type: industriel

status_simplified: Completed


title: Etude pilote évaluant l’intérêt d’une intensification par maraviroc (Celsentri®) chez des patients infectés par le VIH-1 présentant une restauration immunitaire insuffisante malgré une charge virale contrôlée par un traitement anti-rétroviral.

acronym: MARIMUNO

lead_sponsor: Agence nationale de recherches sur le sida et les hépatites virales. ANRS.

lead_sponsor_type: academique


title: Etude de phase II randomisée évaluant l'immunogénicité et la tolérance du vaccin antigrippal A(H1N1)v adjuvanté comparativement au vaccin antigrippal A(H1N1)v non adjuvanté chez des patients infectés par le VIH (ANRS 151 HIFLUVAC)

acronym: HIFLUVAC

lead_sponsor: Agence nationale de recherches sur le sida et les hépatites virales


title: Etude pilote de la pharmacocinétique, de la tolérance et de l’efficacité du raltégravir associé à deux molécules actives parmi les analogues nucléosi(ti)diques et l’enfuvirtide, avant et après transplantation hépatique chez des patients VIH+ en insuffisance hépatique sévère.

acronym: LIVERAL


title: Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance de l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d’hépatite chronique C de génotype 1

acronym: COAT-IFN

lead_sponsor: ANRS


title: Etude Prospective Randomisée Ouverte et Multicentrique évaluant les effets sur les fonctions cognitives de l’hormonothérapie adjuvante dans le cancer du sein de la femme ménopausée

acronym: MNEMOSYNE

lead_sponsor: Centre Oscar Lambret


title: Etude pilote, multicentrique, évaluant l’efficacité d’un traitement anti VHC optimisé (induction par 360µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la réponse virologique à S12, allongement jusqu'à S72 de la bithérapie anti VHC, avec mesures d'accompagnement) sur la réponse virologique soutenue chez des patients VHC de génotype 1 et 4, non répondeurs et co-infectés par le VIH.

acronym: ETOC


title: Etude de phase II randomisée d’évaluation de la faisabilité d’une chimiothérapie par docetaxel prednisone sur un mode hebdomadaire ou toutes les 3 semaines dans une population de patients âgés (+75ans) «vulnérables » ou « fragiles », définis selon les critères de la SIOG, porteurs d’un adénocarcinome de prostate métastatique réfractaire à la castration et progressif.

lead_sponsor: FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)


title: PROTOCOLE D’ANALGESIE POST OPERATOIRE PAR INFILTRATION CONTINUE DE ROPIVACAINE DANS LES ARTHRODESES DU RACHIS LOMBAIRE

lead_sponsor: CHU de Nice


title: ACTION OF THE AMANTADINE ON POST STROKE APHASIC PATIENTS LANGUAGE AND COMMUNICATION

lead_sponsor: Centre hospitalier universitaire de nice


title: An Open-Label Phase I/II Dose Finding Study to evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of BV-101 in Adult Subjects with Early Manifest Huntington's Disease (HD)

lead_sponsor: Brainvectis

status: Ongoing

status_simplified: Ongoing


title: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)

lead_sponsor: AB Science

status: Prohibited by CA

status_simplified: Unknown


title:
Cell therapy in Critical Limb Ischemia by implantation of allogeneic umbilical cord-derived mesenchymal stem cells

 Thérapie cellulaire allogénique de l’ischémie critique des membres inférieurs par implantation de cellules souches mésenchymateuses de cordon ombilical.

acronym:
CLI

 CLI

lead_sponsor: Centre Hospitalier Universitaire de Reims


title: LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction

acronym: LEONARD

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS


title:
Optimization of the management of drepanocytosis patients  treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up

 Optimisation de la prise en charge des patients drépanocytaires  traités par hydroxyurée : Intérêt du suivi thérapeutique pharmacologique

acronym:
OPTIMDREP

 OPTIMDREP

lead_sponsor: Les Hôpitaux Universitaires de Strasbourg


title: Arthrose érosive des doigts : traitement par méthotrexate versus placebo- évaluation de l’action clinique et structurale (IRM dédiée)- Etude ADEM

lead_sponsor: CHU de NICE


title: Oral alendronate for osteoporosis treatment in non-walking children with cerebral palsy

status: Prematurely Ended


title: Traitement de la péricardite aiguë bénigne : Aspirine en cure courte versus traitement prolongé. Essai contrôlé multicentrique en double aveugle de non-infériorité

acronym: PERICARDITE

lead_sponsor: CHU de Brest


title: Evérolimus comme traitement après embolisation ou chimioembolisation de métastases hépatiques de tumeur endocrine digestive

acronym: EVACEL

lead_sponsor: Fédération Francophone de Cancérologie Digestive


title: Cohorte multicentrique nationale de patients atteints de grippe pandémique (nouveau virus A/H1N1v d’origine porcine)

acronym: Etude Flu Co

lead_sponsor: INSERM


title: Traitment of recessive nonbullous congenital ichthyosis with topic Epigallocatechin.

lead_sponsor: Nice University Hospital


title: Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity.

acronym: TIM-DEPIST

lead_sponsor: CHU de Bordeaux


title:
Impact évaluation of an ivermectin single dose administration in the early phase of COVID-19  to negative viral load in SARS-CoV-2 determined by RT-PCR_ IVERCoV.

 Évaluation de l'impact de l'administration d'une dose unique d'ivermectine en phase précoce de la COVID-19 sur le délai de négativation de la charge virale en SARS-CoV-2 déterminée  par RT-PCR_ IVERCoV.

acronym:
IVERCoV

 IVERCoV

lead_sponsor: Raincy Montfermeil intercommunal hospital group


title: Etude de phase I-II de radiochimiothérapie associée au panitumumab dans le traitement des carcinomes épidermoïdes localisés de l'anus


title:
Chemoembolisation of patient with hepatocellular carcinoma, not selective for a curative treatment, by microsphere charged with idarubicin

 Chimioembolisation des carcinomes hépatocellulaires ne relevant pas d'un traitement curatif, par billes chargées en idarubicine

acronym:
IDASPHERE II

 IDASPHERE II


title: Essai de phase II, multicentrique, évaluant le G-CSF en prophylaxie primaire associé au schéma de chimiothérapie FOLFIRI + bévacizumab en 1ère ligne dans le cancer colorectal métastatique chez des patients, homozygotes pour le polymorphisme UGT1A1*28 du promoteur du gène codant pour l’enzyme UGT1A1

lead_sponsor: Fédération Francophone de Cancérologie Digestive - FFCD


title: Carcinome hépatocellulaire avancé sur cirrhose Child B : étude de tolérance et d’efficacité du Torisel® (Temsirolimus)

acronym: FFCD 0903

lead_sponsor: Francophone de Cancérologie Digestive (FFCD)


title:
Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter study

 TRAITEMENT INTRA ARTERIEL PAR DES MICROBILLES CHARGEES D‘IRINOTECAN (DEBIRI) CONCOMITANT A UNE CHIMIOTHERAPIE SYSTEMIQUE PAR FOLFOX CHEZ DES PATIENTS ATTEINTS D’UN CANCER COLORECTAL AVEC METASTASES HEPATIQUES NON RESECABLES – PHASE II MULTICENTRIQUE NON RANDOMISEE

acronym:
DEBIRI

 DEBIRI

lead_sponsor: Fédération Francophone de Cancérologie Digestive (FFCD)


title:
EFFICACY AND SAFETY of aflibercept ASSOCIATED WITH A FOLFIRI CHEMOTHERAPY IN 1ST LINE TREATMENT OF PATIENTS SUFFERING FROM METASTATIC COLORECTAL CANCER  Phase II - single arm - multicenter

 EFFICACITE ET TOLERANCE DE L’AFLIBERCEPT ASSOCIE A UNE CHIMIOTHERAPIE PAR FOLFIRI EN 1ERE LIGNE DE TRAITEMENT CHEZ DES PATIENTS ATTEINTS D’UN CANCER COLORECTAL METASTATIQUE Phase II monobras - multicentrique

acronym:
FFCD1302

 FFCD1302


title:
FFCD 1703 -POCHI
 PEMBROLIZUMAB IN COMBINATION WITH XELOX BEVACIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE: A PROOF OF CONCEPT STUDY
 Phase II – non-randomised- multicentre

acronym: POCHI

lead_sponsor: Federation Francophone de Cancerologie Digestive


title:
A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarcinoma

 Essai de phase II randomisé multicentrique évaluant un traitement séquentiel par nab-paclitaxel + gemcitabine et FOLFIRI.3 versus nab-paclitaxel + gemcitabine en 1ière ligne dans les cancers du pancréas métastatique

acronym:
FIRGEMAX

 FIRGEMAX


title: Etude de phase II non contrôlée: traitement de première ligne par sunitinib plus folfiri pour les patients ayant un cancer du rectum avec des métastases synchrones résécables (SUREMETS)


title: TRAITEMENT NEOADJUVANT DU CANCER DE L’ŒSOPHAGE OPERABLE A VISEE CURATIVE PAR 5-FLUOROURACILE, CISPLATINE ET CETUXIMAB + RADIOTHERAPIE CONCOMITANTE. ÉTUDE DE PHASE I-II

acronym: FFCD 0505


title: Essai évaluant l'efficacité et la tolérance d'une chimiothérapie péri-opératoire par 5FU-Cisplatine-Cetuximab dans les adénocarcinomes de l'estomac et de la jonction oesogastrique. Phase II monobras, multicentrique.


title: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapyfor high risk polycythemia vera

acronym: MITHRIDATE

lead_sponsor: UNIVERSITY OF BIRMINGHAM


title:
A PHASE II TRIAL EVALUATING COMBINATION OF ATEZOLIZUMAB, WITH VENETOCLAX AND OBINUTUZUMAB FOR RELAPSED/REFRACTORY LYMPHOMAS

 ETUDE DE PHASE II EVALUANT LA COMBINAISON ATEZOLIZUMAB, AVEC VENETOCLAX ET OBINUTUZUMAB CHEZ DES PATIENTS ATTEINTS DE LYMPHOME EN RECHUTE OU REFRACTAIRE

lead_sponsor: LYSARC


title: Etude multicentrique de phase II évaluant une supplémentation en vitamine D à haute dose dans la correction de la carence vitaminique D des patientes prises en charge par chimiothérapie adjuvante pour un cancer du sein.

acronym: OPTIVIT

lead_sponsor: ICM- VAL D’AURELLE


title: Lessening Organ Dysfunction with VITamin C (LOVIT)

acronym: LOVIT

lead_sponsor: Université de Sherbrooke


title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the intensive care unit

lead_sponsor: Assistance Publique Hôpitaux de Paris/DRCI


title: Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer

acronym: APOLON

lead_sponsor: UNICANCER


title: Palatability testing in children of a new paediatric formulation of Racecadotril as oral suspension strawberry-flavored administered via an oral graduated syringe compared to the current formulation (apricot-flavored oral powder in sachet to be diluted).

lead_sponsor: BIOPROJET PHARMA


title:
Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19

 Etude multicentrique, randomisée, de l’efficacité et la sécurité  de la Bithérapie Hydroxychloroquine + Azithromycine comparée à une Monothérapie par Hydroxychloroquine chez des adultes hospitalisés pour une infection COVID-19  avec une pneumonie non réanimatoire

lead_sponsor: University Hospital of Montpellier


title:
SPironolactONe for the maintenance of Sinus Rhythm in hypertensive patients with atrial fibrillation and preserved left ventricular ejection fraction: a Prospective Randomized Open Blinded End-point (PROBE) multicenter study (SPONSoR study).

 SPIRONOLACTONE POUR LE MAINTIEN D’UN RYTHME SINUSAL EN PREVENTION DES RECIDIVES DE FIBRILLATION ATRIALE CHEZ LES PATIENTS HYPERTENDUS ET AVEC UNE FRACTION D’EJECTION VETRICULAIRE CONSERVEE (SPONSOR)

acronym:
SPONSoR

 SPONSoR

lead_sponsor: CHU CAEN Normandie


title:
Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE

 Certolizumab en prévention de complications de la grossesse chez les patientes à haut risque atteintes d’un Syndrome des Antiphospholipides (SAPL) et/ou d’un Lupus Erythémateux Systémique et porteuse de l’anticorps Anticoagulant circulant (ACC) de type lupique (IMPACT)

acronym:
IMPACT

 IMPACT

lead_sponsor: University of Utah


title: A Randomized, Single-Blind Study to Evaluate the Pharmacokinetics (PK), and Pharmacodynamics (PD) of INS1007 Administered for 12 Weeks in Subjects with Granulomatosis with Polyangiitis (GPA)

lead_sponsor: Insmed Incorporated


title:
A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases

 Etude de phase II évaluant les nanoparticules AGUIX® en combinaison avec la radiothérapie stéréotaxique pour le traitement des oligo-métastases cérébrales.

acronym:
Nanostéréo

 Nanostéréo

lead_sponsor: Centre Léon Bérard


title:
Impact of a treatment with zoledronic acid on bone mineral density in patients with metastatic castration-resistant prostate cancer, chemo-naïve and receiving abiraterone acetate

 Impact d’un traitement par acide zolédronique sur la densité osseuse chez des patients atteints de cancer de la prostate métastatique résistant à la castration, chimio-naïfs et recevant un traitement par acétate d’abiratérone

acronym:
AZALEE

 AZALEE

lead_sponsor: Centre Oscar Lambret


title: Essai de phase II multicentrique sur le traitement préventif de la folliculite induite par les anti-EGFR chez des patients atteints de cancer colorectal métastatique sous Cetuximab ou atteints de cancer bronchique non à petites cellules sous Erlotinib

acronym: DIPROCOL


title: Etude pharmacologique du Pemetrexed (Alimta) administré avec Cisplatine  et supplémentation vitaminique chez des patients porteurs d'un mésothéliome pleural non résécable

acronym: ALIMESO


title: BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation.

acronym:
FILOCLL13-BLINART

 FILOCLL13-BLINART

lead_sponsor: FILO


title:
Transfusion savings in heart surgery: impact of individual strategy, optimized by erythropoietin (EPO) and metabolic adjustment (ScvO2)

 Epargne transfusionnelle en chirurgie cardiaque : impact d’une stratégie individualisée, optimisée par Erythropoïétine (EPO) et ajustement métabolique (ScvO2)

acronym:
BLOOCOST

 BLOOCOST

lead_sponsor: University hospital of Montpellier


title: IMPACT D’UN FLASH PREOPERATOIRE DE CORTICOÏDES SUR LA MORBIDITE APRES RESECTION COLORECTALE : ETUDE PILOTE PROSPECTIVE MONOCENTRIQUE

acronym: Corticolon

lead_sponsor: CHU Dijon Bourgogne


title:
Study phase II open label study using triheptanoin in patients with a deficiency of glmucose transporter type 1 (GLUT-1)

 Etude de phase II en ouvert utilisant la triheptanoïne chez des patients souffrant d'un déficit en transporteur de glucose de type 1 (GLUT-1)

acronym: GLUTHEP

lead_sponsor: INSERM


title: PRETTINEO PREmedication Trial for Tracheal Intubation of the NEOnate

acronym: PRETTINEO

lead_sponsor: Centre Hospitalier Intercommunal de Créteil


title: Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine

lead_sponsor: Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection


title:
CERVICAL PREPARATION UNDER  PARACERVICAL BLOCK FOR THE ABORTION OF FIRST TRIMESTER: RANDOMIZED TRIAL

 PREPARATION CERVICALE DES IVG SOUS BLOC PARACERVICAL AU 1er TRIMESTRE: ESSAI CLINIQUE RANDOMISE

acronym:
BPCEN

 BPCEN

lead_sponsor: Assistance Publique Hôpitaux de Marseille


title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

lead_sponsor: Janssen-Cilag International NV


title:
CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-metastatic breast cancer after adjuvant post-operative breast irradiation

 CICA-RT – Etude multicentrique randomisée de phase III évaluant l’efficacité de la pommade Cicaderma® versus la pratique courante de chaque centre sur la prévention des radiodermites après prise en charge adjuvante par irradiation mammaire post-opératoire chez des patientes atteintes d’un cancer du sein non métastatique

acronym:
CICA-RT

 CICA-RT


title:
Mesure de la clairance plasmatique du iohexol chez les patients sortant de réanimation après insuffisance rénale aiguë

 Mesure de la clairance plasmatique du iohexol chez les patients sortant de réanimation après insuffisance rénale aiguë

acronym:
IOXSOR

 IOXSOR

lead_sponsor: CHU Angers


title: A phase II study of GDC-0449 in patients with advanced chondrosarcomas.

acronym: CHONDROG

lead_sponsor: Institut Bergonié


title:
Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in patients with metastatic or unresectable leiomyosarcoma (uterine or soft tissue)

 Étude de phase III multicentrique randomisée comparant l’efficacité de l’association doxorubicine et trabectédine, suivie de trabectédine seule en l’absence de progression, à celle de la doxorubicine seule, en traitement de première ligne des patients qui présentent un léiomyosarcome (utérin et des tissus mous) métastatique et/ou localement avancé

lead_sponsor: GUSTAVE ROUSSY


title: An open-label, non-comparative, multicentre study to evaluate the acceptability of a new paediatric formulation of hydroxycarbamide in children with sickle cell disease

lead_sponsor: Addmedica


title: Tumescent anesthesia efficiency in pain management during a dynamic phototherapy session in vertex actinic keratosis treatment: a single-center prospective randomized study.

lead_sponsor: CHU de Poitiers


title: EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer: the ENHANCE prospective feasibility trial.

lead_sponsor: Institut Mutualiste Montsouris


title:
Evaluation of low dose colchicine and ticagrelor in prevention of ischemic stroke in patients with stroke due to atherosclerosis.
 “Reducing inflammation in ischemic stroke with colchicine (riisc), and ticagrelor in high-risk patients-extended treatment in ischemic stroke (thetis”)

 ÉVALUATION D’UNE FAIBLE DOSE DE COLCHICINE ET DE TICAGRELOR EN PREVENTION D’UNE RECIDIVE D’INFARCTUS CEREBRAL CHEZ DES PATIENTS QUI ONT EU UN INFARCTUS CEREBRAL OU UN ACCIDENT ISCHEMIQUE CEREBRAL TRANSITOIRE D’ORIGINE ATHEROSCLEREUSE

acronym:
RIISC THETIS

 RIISC THETIS

lead_sponsor: APHP DRCI


title:
Efficiency of a composite personalised care on functional outcome in early psychosis:  A Prospective Randomised Controlled Trial - PsyCARE_Trial

 Efficacité d'une prise en charge personnalisée composite sur les résultats fonctionnels dans la psychose précoce : un essai contrôlé randomisé prospectif.

acronym: PSYCARE

lead_sponsor: GHU Paris Psychiatrie et Neurosciences


title:
multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains after a primary surgery for breast cancer ( CAPTRANE)

 Etude multicentrique, ouverte, randomisée, comparant le traitement topique par patch de capsaïcine à 8% (Qutenza) à la prégabaline per os dans le traitement précoce des douleurs neuropathiques après une chirurgie primaire pour cancer du sein (CAPTRANE)

acronym: CAPTRANE

lead_sponsor: INSTITUT DE CANCEROLOGIE DE L'OUEST


title:
The impact of deep versus standard muscle relaxation on intra-operative safety during laparoscopic surgery: a multicenter strategy study – EURO RELAX STUDY

 L'impact de la relaxation musculaire profonde comparé à la relaxation musculaire standard sur la sécurité per-opératoire pendant la chirurgie laparoscopique : une étude stratégique multicentrique - Etude EURO RELAX

acronym:
EURO RELAX STUDY

 Etude EURO RELAX

lead_sponsor: CHRU de Nancy


title: A Phase II Safety Trial of Nivolumab in Patients with Metastatic Renal Cell Carcinoma Who Have Progressed During or After Prior Systemic Anti-Angiogenic Regimen

acronym: NIVOREN

lead_sponsor: UNICANCER


title:
Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant

 Etude multicentrique randomisé de phase II, en double aveugle, comparant l’association Taxotère plus curcumine versus Taxotère plus placebo en première ligne de traitement des cancers de la prostate métastatiques résistants à la castration

acronym:
CURTAXEL

 CURTAXEL

lead_sponsor: Centre Jean Perrin


title:
Infections urinaires masculines à entérobactéries productrices de bêta-lactamase à spectre étendue avec résistance associée  aux fluoroquinolones et au cotrimoxazole : efficacité clinique de fosfomycine trométamol per os

 Infections urinaires masculines à entérobactéries productrices de bêta-lactamase à spectre étendue avec résistance associée  aux fluoroquinolones et au cotrimoxazole : efficacité clinique de fosfomycine trométamol per os

acronym:
FOSF’HOM

 FOSF’HOM

lead_sponsor: CHRU de Besançon


title:
Using INDOcyanine green to analyse ovarian vascularization after ovarian laparoscopic CYStectomy,  Diagnostic study of feasibility.

 Étude de la vascularisation ovarienne après traitement coelioscopique des KYStes ovariens, grâce à l’injection de vert d’INDOcyanine. Étude diagnostique de faisabilité.

acronym:
KYSINDO

 KYSINDO

lead_sponsor: CHU CLERMONT FERRAND - DRCI


title: Phase III Trial to assess impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in infertile women presenting with adenomyosis.

acronym: ADENOFIV

lead_sponsor: University Hospital Toulouse


title:
Effet pharmacométabolomique des statines : Etude METASTATINE

 Effet pharmacométabolomique des statines : Etude METASTATINE

acronym:
METASTATINE

 METASTATINE

lead_sponsor: Societe Francaise de Cardiologie


title:
A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporal photopheresis (ECP) as first-line treatment of standard risk Grade II acute graft-versus-host disease after allogeneic stem cell transplantation

 Etude randomisée multicentrique de phase II comparant l’association corticoïdes et photophérèse extracorporelle au traitement conventionnel par corticoïdes dans le traitement de première ligne de la réaction aiguë du greffon contre l’hôte de grade II avec atteinte cutanée survenant après allogreffe de cellules souches hématopoïétiques

acronym:
ECP-aGVHD

 PEC-aGVHD


title: PHASE II RANDOMISEE EVALUANT L’EFFICACITE ET LA TOLERANCE DE 2 STRATEGIES THERAPEUTIQUES COMBINANT LE BEVACIZUMAB A LA CHIMIOTHERAPIE: DESESCALADE VERSUS ESCALADE CHEZ DES PATIENTS AYANT UN CANCER COLORECTAL METASTATIQUE NON RESECABLE ET NON PRE-TRAITE

acronym: HIGHLIGHT

lead_sponsor: Fédération Francophone de Cancérologie Digestive


title:
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure

 Etude de phase II évaluant l’efficacité et la tolérance du Cabozantinib dans le traitement du cancer du col avancé ou métastatique après échec d’un traitement par sel de platine

lead_sponsor: Centre François Baclesse


title:
Phase II randomized study evaluation of FOLFIRINOX +/- LV5FU2 in maintenance and FIRGEM in 1rst line of metastatic pancreas cancer

 Phase II randomisée dans le cancer pancréatique métastatique évaluant le FOLFIRINOX +/- LV5FU2 en entretien dans le cancer pancréatique métastatique

acronym:
PANOPTIMOX

 PANOPTIMOX


title: Intermittent cefoxitin administration versus loading bolus followed by continuous infusion for the prevention of surgical site infection in colorectal surgery: a multicentre, double-blind, randomized controlled clinical trial


title:
Impact of the increase in post-filter ionized calcemia target on the efficacy of regional citrate anticoagulation during continuous renal replacement therapy in intensive care: multicenter randomized controlled non-inferiority study.

 Impact de l’augmentation de la cible de calcémie ionisée post-filtre sur l’efficacité de l’anticoagulation régionale au citrate au cours d’une épuration extra-rénale continue en réanimation : étude de non infériorité contrôlée randomisée multicentrique.

acronym:
CA-CIBLE

 CA-CIBLE

lead_sponsor: ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP)


title:
EFFECT OF AZITHROMYCIN ON THE PROPORTION OF FAILURES OF SEVERE PERIODONTITIS NON-SURGICAL TREATMENTS : A RANDOMIZED, DOUBLE-BLIND VERSUS PLACEBO STUDY

 EFFET DE L'AZITHROMYCINE SUR LA PROPORTION D'ECHECS DES TRAITEMENTS NON-CHIRURGICAUX DES PARODONTITES SEVERES : ETUDE RANDOMISEE, EN DOUBLE AVEUGLE VERSUS PLACEBO

acronym:
AZITHROPARO

 AZITHROPARO

lead_sponsor: Hôpitaux Universitaires de Strasbourg


title: An Open-label, Non-controlled, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of Allogeneic Human Liver Stem Cells (HLSCs) in the Treatment of Pediatric Patients with Early-onset Urea Cycle Disorder

lead_sponsor: Unicyte AG


title: Evaluation of preference for a buprenorphine-based maintenance therapy, after a switch from buprenorphine alone (Subutex®) to the buprenorphine/naloxone combination (Suboxone®), in opioid-dependent patients with buprenorphine maintenance therapy

lead_sponsor: Schering-Plough


title:
Severe erythema multiforme: A randomized controlled trial comparing a short systemic corticosteroids regimen to placebo in the acute established phase

 Erythème polymorphe grave : étude contrôlée randomisée comparant une corti-cothérapie systémique courte à un placebo dans la phase aigüe constituée

acronym: SEM-CORTICO (Severe Erythema Multiforme - CORTICO)

lead_sponsor: Assistance Publique - Hôpitaux Paris (Direction de la Recherche Clinique et de l’Innovation)


title:
Evaluation of the effectiveness and safety of ethosuximide in the treatment of abdominal pain associated with irritable bowel syndrome

 Evaluation de l’efficacité et de la tolérance de l’éthosuximide dans le traitement de la douleur abdominale liée au syndrome de l’intestin irritable

acronym:
IBSET

 IBSET

lead_sponsor: CHU CLERMONT-FERRAND


title: Essai pilote multicentrique évaluant la capacité d’une stratégie de traitement antirétroviral intermittent à maintenir une stabilité immunologique chez des patients infectés par le VIH-1, jamais traités et ayant un nombre de lymphocytes CD4 > ou = 500 par mm3.

acronym: TIPI

lead_sponsor: Agence nationale de recherches sur le sida et les hépatites virales. ANRS.


title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previously untreated adults with B and C Binet stage B-chronic lymphoid leukemia (B-CLL).

acronym: CLL 2007 FMP

lead_sponsor: GOELAMS


title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB)

lead_sponsor: Genentech, Inc.


title: Essai clinique multicentrique, randomisé et contrôlé comparant l’efficacité de la pioglitazone versus placebo chez les patients avec hépatite virale chronique C de génotype non-2, non-3, insulinorésistance et traités par bithérapie interféron pégylé ribavirine.

acronym: PEGLIST

lead_sponsor: ANRS


title:
SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation.
 An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients with Atrial Fibrillation undergoing Electric Cardioversion Following Transesophageal Echocardiography.

acronym: SAFE-AF

lead_sponsor: GlaxoSmithKline R & D


title: Essai clinique multicentrique, ouvert, prospectif évaluant l’efficacité d’une supplémentation par vitamine D en association à une bithérapie par interféron alpha pégylé plus ribavirine chez les patients avec une hépatite virale chronique C de génotype 1 ou 4, non répondeurs à une première bithérapie

acronym: ANRS HC 25  VITAVIC


title: A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia

lead_sponsor: Clavis Pharma ASA


title:
Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent

 Stratégie anti-infectieuse postopératoire après une duodénopancréatectomie chez les patients ayant un stent biliaire préopératoire

acronym:
FRENCH24 ANIS

 FRENCH24 ANIS

lead_sponsor: CHU de Rouen


title:
A phase I/II multicenter, open-label study of CLR457 administered orally
 in adult patients with advanced solid malignancies

lead_sponsor: Novartis Pharma Services AG


title: Etude contrôlée, randomisée en double aveugle versus placebo de l’efficacité de la spécialité homéopathique BRN-01 dans le traitement des bouffées de chaleur de la femme ménopausée

lead_sponsor: LABORATOIRES BOIRON


title: A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias

lead_sponsor: Osmotica Pharmaceutical Corp.


title:
Etude d’évaluation de l’effet de Cuprum Metallicum 15 CH sur les crampes musculaires survenant en cours de dialyse chez des patients hémodialysés chroniques.
 Effect of Cuprum Metallicum 15 CH on muscle cramps at dialysis, evaluation study in chronic hemodialysed patients

lead_sponsor: Laboratoire BOIRON


title:
IFM 2014-02 study: A randomized phase III study of Bortezomib-Melphalan 200 conditioning regimen versus Melphalan 200 for frontline transplant eligible patients with multiple myeloma

 Etude IFM 2014-02:
 Intérêt d’un conditionnement par bortezomib-melphalan 200 vs melphalan 200 suivi d’une autogreffe de cellules souches chez les patients de moins de 66 ans atteints de myélome multiple en première ligne: une étude randomisée de phase III de l’IFM

acronym: Etude IFM 2014-02

lead_sponsor: CHU Toulouse


title: Essai clinique contrôlé randomisé, multicentrique, évaluant l'efficacité de deux médicaments homéopathiques (Dopamine 5 CH et Serotoninum muriaticum 5 CH) chez l'enfant TDAH âgé de 3 à 7 ans (6 ans et 11 mois).

acronym: HYP-HOPE

lead_sponsor: Laboratoires BOIRON


title:
A phase II trial evaluating conformational intensity modulated radiotherapy with concomitant nivolumab followeb by nivolumab for patients with locally advanced non-small cell lung cancer

 Essai de phase II évaluant l'association d'une radiothérapie conformationnelle avec modulation d'intensité-Nivolumab suivi d'une maintenance par Nivolumab dans les cancers pulmonaires non à petites cellules localement avancés

acronym:
AIRING

 AIRING

lead_sponsor: Centre Régional de lutte contre le Cancer Eugène Marquis


title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in Patients with Previously Treated, incurable Ewing Sarcoma

lead_sponsor: Sarcoma Alliance for Research Through Collaboration (SARC)


title: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia (MW)

acronym:
REMODEL-WM3

 REMODEL-WM3

lead_sponsor: FILO


title: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer

acronym: TENACITY

lead_sponsor: Ayala Pharmaceuticals, Inc.


title:
AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé en simple aveugle comparant les effets neurocognitifs du rivaroxaban par rapport à un antagoniste de la vitamine K

 AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé en simple aveugle comparant les effets neurocognitifs du rivaroxaban par rapport à un antagoniste de la vitamine K

acronym:
ACCOG

 ACCOG

lead_sponsor: CHU ANGERS


title: Autologous transplantation of Adipose tissue derived mesenchymal Stroma/stem Cells (ASC) in patients with critical limb ischemia: a phase II study (ACellDream 2).

acronym: ACellDREAM 2

lead_sponsor: University Hospital Toulouse


title:
Multicentre, cross-over, PRAgmatic trial in Atopic Dermatitis testing long-term control effectiveness of new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation vs. placebo in a randomised, parallel-group trial

 Etude PRAgmatique, multicentrique, en cross-over, évaluant chez des sujets atteints de Dermatite Atopique, l’efficacité sur le contrôle à long terme d’un nouveau protocole de photothérapie durant l’hiver, en traitement “add-on”, avec ou sans supplémentation en vitamine D dans un essai randomisé en groupe parallèle

acronym:
PRADA

 PRADA

lead_sponsor: CHU de Rennes


title:
Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial

 Traitement par inhibiteur de l’HMG-CoA réductase (simvastatine) des anomalies de la croissance et de l’os des enfants présentant un syndrome de Noonan :
 un essai thérapeutique de phase III, multicentrique, randomisé, contrôlé contre placebo, en double aveugle.

acronym:
RASTAT

 RASTAT


title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therapy) administered in combination with anti-VEGF therapy

lead_sponsor: OPHTHOTECH CORPORATION


title:
Comparison of the efficacy and safety of budesonide/formoterol Turbuhaler® versus terbutaline nebulization as reliever therapy in children with asthma presenting at the emergency room for moderate exacerbation

 Comparaison de l’efficacité et de la sécurité du budenoside/formoterol Turbuhaler® par rapport à la terbutaline en nébulisation pour le traitement de la crise d’asthme chez les enfants se présentant aux urgences pour une exacerbation modérée

acronym: ASTHMAFAST

lead_sponsor: Centre Hospitalier Intercommunal de Créteil


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis

acronym: Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS

lead_sponsor: Biogen Idec Research Limited


title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

lead_sponsor: Incyte Corporation


title: A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders.

lead_sponsor: Neurochlore


title:
A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome

 Étude de phase II multicentrique non-randomisée évaluant le traitement par un inhibiteur d’IDH1 (AG-120) chez des patients présentant un syndrome myélodysplasique avec mutation IDH1

lead_sponsor: Groupe Francophone des Myelodysplasies


title:
A Multicenter Open label Phase II study of Pomalidomide and Cyclophosphamide and Dexamethasone in relapse/refractory Multiple Myeloma patients who were first treated within the IFM/DFCI 2009 trial

 Etude multicentrique, ouverte, de phase II, évaluant l’association pomalidomide, cyclophosphamide et dexaméthasone chez des patients atteints d’un myélome multiple en rechute ou réfractaire après un premier traitement selon le protocole IFM/DFCI 2009

acronym: PCD

lead_sponsor: INSTITUT CURIE


title: A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders


title:
A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB) before Breast Cancer Surgery: Effects on acute Postoperative Pain

 Essai clinique randomisé de non-infériorité, multicentrique en double aveugle, évaluant l’effet du bloc érecteur (ESP) versus bloc paravertébral (BPV) sur la douleur aiguë après chirurgie carcinologique du sein

acronym:
ER-One

 ER-One


title: Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy

lead_sponsor: AXCAN PHARMA SAS


title:
Assessment of Beta blocker interruption after uncomplicated mYocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization: The ABYSS Study

 Evaluation de l'arrêt de l'administration de bêta-bloquant après un infarctus du myocarde non compliqué sur l'incidence des évènements cardiaques symptomatiques nécessitant une hospitalisation. Etude ABYSS

acronym: ABYSS

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: Identification des sources génétiques de variabilité de l'adaptation de la repolarisation ventriculaire à un stimulus pharmacologique et physiologique dans une population apparemment normale

acronym: GENEREPOL


title: Efficacité du levetiracetam intra-veineux en association avec le clonazepam versus clonazepam seul dans la prise en charge pré-hospitalière de l'état de mal épileptique généralisé tonico-clonique

acronym: SAMUKEPPRA


title: Durvalumab/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by electroporation ablation in curative intent: French multicenter phase 2 therapeutic DUMELEP trial (DUMELEP)

acronym: DUMELEP

lead_sponsor: Assistance publique - Hôpitaux de Paris


title:
Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-label, non-inferiority trial

 Comparaison de la rifabutine et de la rifampicine dans le traitement des infections ostéoarticulaires sur prothèse à staphylocoque prises en charge par synovectomie-lavage et antibiothérapie : un essai multicentrique randomisé ouvert de non infériorité

acronym: RIFAMAB

lead_sponsor: CH Tourcoing


title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06)

acronym: VAPOR (GETUG T06)

lead_sponsor: GUSTAVE ROUSSY


title:
FFCD 1102
 ETUDE DE PHASE II : TRAITEMENT DE PREMIERE LIGNE PAR FOLFIRINOX POUR LES PATIENTS AYANT UN CANCER DU RECTUM AVEC METASTASES SYNCHRONES NON RESECABLES

 FFCD 1102
 ETUDE DE PHASE II : TRAITEMENT DE PREMIERE LIGNE PAR FOLFIRINOX POUR LES PATIENTS AYANT UN CANCER DU RECTUM AVEC METASTASES SYNCHRONES NON RESECABLES

acronym:
FFCD 1102

 FFCD 1102

lead_sponsor: Fédération Francophone de Cancérologie Digestive (FFCD)


title:
Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis

 Etude de l’intérêt d’un traitement précoce par un inhibiteur de l’endothéline  (Bosentan) chez des patients présentant une cécité brutale secondaire à une artérite à cellules géantes

acronym:
CECIBO

 CECIBO

lead_sponsor: CHU de Nice


title:
Aprepitant versus Hydroxyzine en association avec les traitements cytoréducteurs pour les patients avec néoplasies myéloprolifératives souffrant d’un Prurit Aquagénique Persistant.

 Aprepitant versus Hydroxyzine en association avec les traitements cytoréducteurs pour les patients avec néoplasies myéloprolifératives souffrant d’un Prurit Aquagénique Persistant.

acronym:
APHYPAP

 APHYPAP

lead_sponsor: CHRU de Brest


title:
Not done

 Comparaison des effets rénaux des solutés de remplissage vasculaire PlASmalyte Viaflo et NaCl 0,9 % au cours de la réanimation de patients TRAUmatisés graves.

acronym: ASTRAU


title:
PARPi-PANC - A multicentric, single arm, phase II trial assessing the efficacy of niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer

 PARPi-PANC - Etude multicentrique, monobras, de phase II évaluant l’efficacité du niraparib en première ligne de traitement chez les patients présentant un cancer du pancréas métastatique avec un déficit de la recombinaison homologue

acronym:
PARPi-PANC

 PARPi-PANC

lead_sponsor: Centre Léon Bérard


title: ETUDE RANDOMISEE EN DEUX GROUPES PARALLELES DE L’EFFICACITE ET DE LA TOLERANCE DE L’ASSOCIATION D'AMYCOR-ONYCHOSET®,  D'AMYCOR® CREME ET DE LA TERBINAFINE VERSUS L ADMINISTRATION DE TERBINAFINE SEULE CHEZ L’ADULTE SOUFFRANT D’ONYCHOMYCOSE(S) AVEC ATTEINTE MATRICIELLE DES ONGLES DES PIEDS

acronym: ATOMYC

lead_sponsor: Merck Serono


title:
A double-blind, randomized, multicenter study evaluating 200 mg versus 600 mg of Mifepristone on pain in voluntary abortion by drug prior to 7 SA. DoMy Study

 Etude multicentrique randomisée en double aveugle évaluant 200 mg versus 600 mg de Mifepristone sur la douleur dans l’interruption volontaire de grossesse par voie médicamenteuse avant 7 SA. Etude DoMy

acronym:
DoMy

 DoMy

lead_sponsor: Assistance Publique Hôpitaux de Marseille


title:
P-glypoprotein inhibition effect on the pharmacokinetics of two tacrolimus formulations: prolonged and extended-release

 Effet De l’inhibition de la glycoprotéine P sur la pharmacocinétique de deux formes galéniques de tacrolimus

acronym:
DIPLOID

 DIPLOID

lead_sponsor: CHU de Rennes


title:
Phase III trial comparing 2 diagnostic strategies for the preoperative localization of parathyroid adenoma in primary hyperparathyroidism:
 TEMP / CT with Tc99m-sestaMIBI or PET / CT with F18-choline in first intention

 Essai de phase III comparant 2 stratégies diagnostiques pour la localisation pré-opératoire d'adénome parathyroïdien dans l'hyperparathyroïdie primaire :
 TEMP/TDM au Tc99m-sestaMIBI ou TEP/TDM à la F18-choline en première intention

acronym:
APACH2

 APACH2

lead_sponsor: Centre François Baclesse


title: Evaluation of Amoxicillin diffusion in breast milk according to a population pharmacokinetic approach.

acronym: CONCEPTION-AMOX

lead_sponsor: CHU TOULOUSE


title: Randomized double blind controlled trial comparing the safety and efficacy of apremilast versus placebo in severe forms of recurrent aphthous stomatitis

lead_sponsor: CHU de Rouen


title: A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator-Associated Pneumonia

lead_sponsor: Janssen Cilag International NV


title: Prévention de la transmission du VIH-1 de la mère à l’enfant sans utilisation d’analogue nucléosidique

acronym: PRIMEVA

lead_sponsor: Agence nationale de recherches sur le sida et les hépatites virales. ANRS


title: A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma

acronym: IGF-1R protocol

lead_sponsor: Cliniques Universitaires Saint Luc-Centre du Cancer


title: A randomized, double blind, multicenter study evaluating efficacy and safety of Clevudine monotherapy versus Tenofovir monotherapy versus combination therapy of Clevudine and Tenofovir for 96 weeks in HBeAg negative patients with chronic hepatitis B, naïve to anti-VHB therapy

lead_sponsor: ANRS


title:
Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients

 Étude de phase 2/3, randomisée, en double aveugle, évaluant l’amisulpride intraveineux comme traitement prophylactique des nausées et vomissements post-opératoires chez les patients pédiatriques

lead_sponsor: Acacia Pharma Ltd


title:
Pharmacokinetic and Placental Transfer of Levetiracetam

 Etude de la pharmacocinétique maternelle et du passage transplacentaire du Lévétiracétam

acronym:
EPICEINTE

 EPICEINTE

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS


title:
A randomized, double-blind, placebo-controlled trial comparing the efficacy and tolerance of sodium oxybate in patients affected with idiopathic hypersomnia.

 Etude bi-centrique contrôlée randomisée en double aveugle évaluant l'efficacité et la tolérance de l'oxybate de sodium chez les patients atteints d'hypersomnie idiopathique.

acronym:
SODHI

 SODHI

lead_sponsor: University Hospital of Montpellier


title: An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of  a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older

lead_sponsor: Sanofi Pasteur MSD S.N.C.


title: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehicle in Subjects with Fuchs Endothelial Corneal Dystrophy (FECD)

acronym: PHANTOM Study

lead_sponsor: SANTEN INCORPORATED


title: A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

acronym: Phase 3 Study of Belantamab Mafodotin Plus VRd vs. VRd in Transplant Ineligible Newly Diagnosed MM

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: AN OPEN LABEL, MULTICENTER EXTENSION STUDY FOR PATIENTS PREVIOSULY ENROLLED IN A GENENTECH AND/OR F. HOFFMAN-LA ROCHE SPONSORED STUDY

lead_sponsor: F. Hoffmann-La Roche Ltd


title:
Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3.

 Vaccination après allogreffe de cellules souches hématopoïétiques : Etude randomisée évaluant l’intérêt d’une injection supplémentaire chez les patients non répondeurs à M3.

acronym:
EVaxAll

 EVaxAll

lead_sponsor: University Hospital Grenoble


title: Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO

acronym: MOIO

lead_sponsor: UNICANCER


title: Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.

lead_sponsor: Orfagen


title: A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT)

lead_sponsor: Unicancer


title: A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older


title:
A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) and in adult volunteers with documented history of SARS CoV-2 infection (of more than 6 months) administered with only one dose of vaccine

 Essai de phase II évaluant l'immunogénicité et la sécurité du vaccin à ARNm COVID-19 BNT162b2 chez des participants adultes sans antécédents d'infection par le SARS CoV-2, administrés avec deux doses de vaccin (J1-J29) et chez des participants adultes ayant des antécédents documentés d'infection par le SRAS CoV-2 (de plus de 6 mois), administrés avec une seule dose de vaccin.

lead_sponsor: Inserm-ANRS


title: Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44

acronym: Principle -TIMI 44

lead_sponsor: Eli Lilly and Company


title: Impact of Gamma-OH on sleep in ICU patients difficult to wean from mechanical ventilation

lead_sponsor: CHU de Poitiers


title: A survey on the success of inhibitor elimination using individualized concentrate selection and controlled immune tolerance induction

acronym: OBSITI

lead_sponsor: CHU de Saint-Etienne


title: An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression.

lead_sponsor: Boehringer Ingelheim France


title: Etude de phase IV, de non infériorité, multicentrique, randomisée, en double aveugle, comparant la pristinamycine (2g x 2 par jour pendant 2 jours puis 1g x 3 par jour pendant 5 à 7 jours) à l’amoxicilline (1g x 3 par jour) pendant 7 à 9 jours chez des adultes présentant une pneumonie aiguë communautaire avec un score PORT de II ou III

lead_sponsor: sanofi-aventis France


title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, 100 and 200 mg) vs Placebo in Patients with Overactive Bladder.

lead_sponsor: Helsinn Healthcare SA


title:
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

 Impact de l’Hormonothérapie Neoadjuvante sur la prise en charge chirurgicale des carcinomes canalaires in Situ étendus

acronym: HORNEO 01

lead_sponsor: INSTITUT DE CANCEROLOGIE DE L'OUEST


title: A MULTICENTER, RANDOMIZED, INTRA-INDIVIDUAL, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD2027 OINTMENT 9µG/G APPLIED TWICE DAILY OVER 4 WEEKS IN THE TREATMENT OF TARGET LESIONS IN ADULTS SUBJECTS WITH ATOPIC DERMATITIS.

lead_sponsor: Galderma R&D SNC


title:
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae Neuropathic Pain.

 Phase II randomisée comparative visant à évaluer l’intérêt du Qutenza dans la prise en charge de patients en rémission de cancer ORL et présentant des douleurs neuropathiques séquellaires.

acronym:
TEC-ORL

 TEC-ORL

lead_sponsor: INSTITUT CLAUDIUS REGAUD


title:
AntiPlatelet theraPy stratEgy followiNg left atrial appenDAGe closurE

 Stratégie d'Antiagrégation Plaquettaire Post ExclusioN De l'Auricule GauchE

acronym:
APPENDAGE

 APPENDAGE

lead_sponsor: CHU de Bordeaux


title:
Etude des effets fonctionnels du nusinersen chez des personnes amyotrophiques spinaux adultes par déficit génétique 5q de type 2 ou 3 : étude expérimentale en cas unique en lignes de base multiples à travers les sujets, multicentrique, randomisée, en simple aveugle

 Etude des effets fonctionnels du nusinersen chez des personnes amyotrophiques spinaux adultes par déficit génétique 5q de type 2 ou 3 : étude expérimentale en cas unique en lignes de base multiples à travers les sujets, multicentrique, randomisée, en simple aveugle

lead_sponsor: Centre Hospitalier Universitaire de Reims


title: Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation

lead_sponsor: Assitance Publique - Hôpitaux de Paris


title: Identification of the optimal combination dosing schedule of nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)

lead_sponsor: GERCOR


title:
Multicentric, double-blind, randomized study to show that the addition of IV tranexamic acid versus placebo in ACL ligamentoplasties leads to a decrease in blood loss and postoperative pain

 Etude multicentrique randomisée en double aveugle visant à montrer que l’adjonction d’acide tranexamique IV versus placebo dans les ligamentoplasties du LCA entraine une diminution de la perte sanguine et des douleurs postopératoires

acronym:
EXACYLCA

 EXACYLCA

lead_sponsor: Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche


title:
Effect of Tinzaparin on inflammatory biomarkers during the acute phase of deep vein thrombosis

 Effet de la Tinzaparine sur les marqueurs inflammatoires sériques à la phase aiguë de la thrombose

lead_sponsor: CHU Amiens-Picardie


title: A phase Ib study of metronomic Cyclophosphamide and Methotrexate combined with Zoledronic acid and Sirolimus in patients with solid tumor with bone metastasis and advanced pretreated Osteosarcoma.

acronym: METZOLIMOS

lead_sponsor: Institut Bergonié


title: A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

lead_sponsor: Pharma Mar, S.A.


title:
First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years -

 Traitement de 1ère intention de patients âgés de 2 à 50 ans atteints de tumeur d’Ewing avec métastases extra-pulmonaires.

lead_sponsor: INSTITUT CURIE


title: Carcinomes Oesophagiens Non opérés traités par Chimioradiothérapie à base d’Oxaliplatine (FOLFOX-4) et Radiothérapie à Dose Elevée (CONCORDE) : Essai de phase II-III

acronym: CONCORDE

lead_sponsor: Centre Georges-François Leclerc


title: A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination with Letrozole as First Line Treatment in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer.

lead_sponsor: Antisoma Research Limited


title: A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma

lead_sponsor: Innate Pharma


title: Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.

lead_sponsor: IBSA, Institut Biochimique SA


title: A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease

acronym: FOEHN

lead_sponsor: Juvantia Pharma Ltd


title: A multicenter phase III randomized study of 153Sm-EDTMP and Docetaxel + Prednisone versus Docetaxel + Prednisone in Taxane-naive patients with metastatic hormone-refractory prostate cancer.

acronym: SAMDOCET


title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

lead_sponsor: MedImmune, LLC


title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)

lead_sponsor: Fondation Charcot Stichting


title: An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15μg) versus an Inactivated adjuvanted Influenza Vaccine administered by Intramuscular Route (Addigrip® 15µg) in subjects 65 years of age or older

lead_sponsor: Sanofi Pasteur MSD


title:
A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

 Étude croisée de phase IIIb, en 2 parties, randomisée, en double aveugle, contrôlée contre placebo avec une période en ouvert à long terme visant à évaluer l’ivacaftor chez des sujets atteints de mucoviscidose âgés de 3 à 5 ans et présentant une mutation de défaut de régulation (classe III) du gène CFTR spécifique

lead_sponsor: Vertex Pharmaceuticals Incorporated


title: PREDICTIVE FACTORS AND MAGNITUDE OF RESPONSE TO OMALIZUMAB AND MEPOLIZUMAB IN ALLERGIC AND EOSINOPHILIC SEVERE ASTHMA: PREDICTUMAB, AN OPEN-LABEL, CONTROLLED, RANDOMIZED MULTINATIONAL PRAGMATIC TRIAL

lead_sponsor: Cliniques Universitaires Saint-Luc


title: Efficacy of recombinant human club (clara) cell 10kDa protein (CC10) administered to premature neonates with respiratory distress syndrome.

lead_sponsor: Therabron Therapeutics Inc.


title:
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

 Étude visant à évaluer la sécurité et l’efficacité de l’APX005M, un anticorps agoniste du CD40, administré en association avec le nivolumab chez des patients présentant un cancer bronchique non à petites cellules ou un mélanome métastatique

lead_sponsor: Apexigen, Inc.


title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis

lead_sponsor: Amgen Inc


title: ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE CORTICOTHÉRAPIE

lead_sponsor: THERABEL LUCIEN PHARMA


title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

acronym: IFM/DFCI 2009

lead_sponsor: CHU de TOULOUSE


title: A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat® administered once daily versus twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD)

lead_sponsor: Novartis Pharma Services AG


title: Standardized sTudy with Almotriptan in eaRly Treatment of migraine, START. An international, open-label, single arm, effectiveness and safety study of Almotriptan in primary care seeting.

acronym: START

lead_sponsor: Laboratorios Almirall SA


title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone.

lead_sponsor: F.Hoffmann-La Roche Ltd


title: A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients with Advanced Solid Tumors

acronym: Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Therapy

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations.

acronym: MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.


title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia (CIN1).

lead_sponsor: Photocure ASA


title: A MULTICENTRE DOUBLE-BLIND RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF GS-101 EYE DROPS, AN ANTISENSE OLIGONUCLEOTIDE, VERSUS PLACEBO ON INHIBITION OF CORNEAL NEOVASCULARIZATION, A MAJOR RISK FACTOR OF CORNEAL GRAFT REJECTION: The I-GRAFT study.

acronym: The I-GRAFTstudy

lead_sponsor: Les Laboratoires CTRS


title:
A multicenter, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic, safety and tolerability study in patients aged 12 to <18 years of age with a central venous catheter to support prediction of the age appropriate dose of ticagrelor with similar levels of inhibition of platelet aggregation to 90 mg bd in adults

 Une étude multicentrique, pharmacocinétique, pharmacodynamique, d’innocuité et de tolérabilité, menée en double aveugle et contrôlée par placebo sur des patients âgés de 12 à <18 ans portant un cathéter veineux central pour aider au calcul de la dose de ticagrelor correspondant à l’âge du patient, avec des niveaux similaires d’inhibition de l’agrégation plaquettaire, de l’ordre de 90 mg bd chez les adultes

lead_sponsor: AstraZeneca AB


title: Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma.


title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF  I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)

lead_sponsor: LFB BIOTECHNOLOGIES


title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma

lead_sponsor: Nerviano Medical Sciences S.r.l.


title:
Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy.
 Étude de phase II , multicentrique, ouverte, clinique et pharmacocinétique de Zalypsis® (PM00104) chez des patients atteints d’un sarcome de la famille des tumeurs d’Ewing (EFT) non resécable, localement avancé et/ou métastatique en progression après au moins une première ligne chimiothérapique

lead_sponsor: Pharma Mar S.A., Sociedad Unipersonal


title: Traitement par lévamisole du syndrome néphrotique corticosensible de l'enfant

acronym: LEVAMISOLE

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with  Relapsed Diffuse Large B-Cell Lymphoma

lead_sponsor: Eli Lilly and Company limited


title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis.

acronym: BATT (Biclutamide anatrozole treatment for testotoxicosis)


title: An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.

lead_sponsor: Bayer AG


title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence

lead_sponsor: Allergan Ltd


title: An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancer

acronym: NERABRAIN

lead_sponsor: Institut Jules Bordet


title: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

lead_sponsor: Hospices Civils de Lyon


title: A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A as compared to the Dresden-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A.

acronym: FLU D-PAN H1N1-017

lead_sponsor: GlaxoSmithKline Biologicals


title: "MULTINATIONAL, PHASE III, RANDOMIZED STUDY TO EVALUATE TREATMENT CUSTOMIZED ACCORDING TO RAP 80 AND BRCA1 mRNA ASSESSMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (modification of the BREC study) "

acronym: BREC

lead_sponsor: ADDS (Advanced Drug Development Services)


title: A Phase I Study of Ridaforolimus in Pediatric Patients with Advanced Solid Tumors

acronym: Oral MK8669 in Children/Adolescents with Solid Tumors (8-17 years)


title: An Open Label Multicenter Extension Study to Evaluate the Long-Term Efficacy and Safety of SBC 102 in Children with Lysosomal Acid Lipase Deficiency Who Previously Received Treatment with SBC-102

acronym: SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency

lead_sponsor: Synageva Biopharma Corp.


title: A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or 5x10E8 TU doses to placebo in HIV-1 clade B infected patients under highly active antiretroviral therapy

lead_sponsor: THERAVECTYS


title: IMPACTS Trial:  Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study:  Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients with Sickle Cell Disease and Vaso-occlusive Crisis)

lead_sponsor: Anthera Pharmaceuticals Incorporated


title: A randomized, double-blind, placebo-controlled, 4 period incomplete block cross-over, multi-center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 in patients with stable Chronic Obstructive Pulmonary Disease (COPD), compared to seven days treatment with tiotropium (18µg once daily, open label) as an active control.

lead_sponsor: Novartis Pharma Services AG


title:
A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma
 Revised Protocol Number 01, incorporating Amendment 02 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY

lead_sponsor: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK


title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of  Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer

lead_sponsor: Bristol Myers Squibb International Corporation


title: A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy

lead_sponsor: Cliniques Universitaires St Luc


title: Phase Ib/II, Multicenter, Open-Label, Randomized, Clinical Study with Dose Optimization of Two Different Schedules of Elisidepsin Trifluoroacetate (Irvalec®) as a Single Agent in Patients with Unresectable, Locally Advanced or Metastatic Esophageal, Esophagogastric Junction or Gastric Cancer After Failure of One but not More than Two Prior Lines of Systemic Therapy

acronym: IMAGE

lead_sponsor: Pharma Mar, S.A. Sociedad Unipersonal


title:
A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients
 Revised Protocol Number 02, incorporating amendments 03 and 04


title:
Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or neither

 Essai clinique randomisé multicentrique du traitement endovasculaire de l’accident vasculaire cérébrale ischémique aigu. Effet du traitement médicamenteux péri-interventionnel : acide acétylsalicylique, héparine non fractionnée, les deux ou aucun

acronym:
MR CLEAN - MED

 MR CLEAN - MED

lead_sponsor: Erasmus MC University Medical Center


title: Sevrage de la ventilation mécanique guidé par le peptide natriurétique de type B.

acronym: BMW

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: ETUDE INTERNATIONALE DE PHASE II EVALUANT UNE ASSOCIATION CHOP-RITUXIMAB AVEC CONSOLIDATION PRECOCE PAR IBRITUMOMAB-TIUXETAN-Y90 CHEZ DES PATIENTS AGES DE 65 ANS A 80 ANS ATTEINTS D'UN LYMPHOME MALIN A GRANDES CELLULES CD20+ NON PRETRAITES

acronym: CHORIZO

lead_sponsor: CENTRE ANTOINE LACASSAGNE


title: A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma

lead_sponsor: Exelixis, Inc.


title: Efficacy and Safety Assessment of Azyter® (T1225) in Peri-Operative Antibio-Prophylaxis (ocular surface decontamination) for Cataract Surgery

lead_sponsor: Laboratoires Théa


title: Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma

lead_sponsor: Amgen Inc


title: A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients with Stages 3 to 5 Chronic Kidney Disease Undergoing MRI with the Injection of ProHance

acronym: Evaluation of the Incidence of NSF Following ProHance Injection

lead_sponsor: Bracco Imaging S.p.A.


title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002

lead_sponsor: Edimer Pharmaceuticals, Inc.


title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease followed by a 38-Week open-label extension phase

lead_sponsor: BIOPROJET


title: FIVHeMA: Intraventricular fibrinolysis versus external ventricular drainage alone in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.

acronym: FIVHEMA

lead_sponsor: CHU CAEN


title: A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINISTERED ORALLY TO SUBJECTS WITH ADVANCED SOLID TUMORS, NON-HODGKIN’S LYMPHOMA OR MULTIPLE MYELOMA

lead_sponsor: Celgene Corporation


title: Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA

lead_sponsor: Abeona Therapeutics Inc


title: A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis

lead_sponsor: Novartis Pharma Services AG


title: An Open-Label Extension Study Evaluating the Long-Term Safety of ICA 17043 with or without Hydroxyurea Therapy in Subjects with Sickle Cell Disease

lead_sponsor: Icagen Inc.


title:
A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism
 Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

acronym: PARTUM

lead_sponsor: CHU SAINT-ETIENNE


title: Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose  péritonéale d'origine colorectale associée à une chimiothérapie systémique.

acronym: CHIP

lead_sponsor: FNCLCC


title: VALIDATION OF DYSKINESIA RATING SCALES

lead_sponsor: Michael J. Fox Foundation for Parkinson’s Research


title:
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia

 Une étude ouverte multicentrique avec titrage de la posologie du chlorhydrate de nevanimibe dans le traitement de l’hyperplasie congénitale des surrénales classique

lead_sponsor: Millendo Therapeutics, Inc.


title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)

lead_sponsor: Fulcrum Therapeutics, Inc.


title: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer

lead_sponsor: ARIAD Pharmaceuticals, Inc.


title: A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

lead_sponsor: Millennium Pharmaceuticals, Inc


title:
A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

 Étude multinationale dans le but de recueillir des échantillons de sang pour l’exploration de paramètres génétiques et de biomarqueurs potentiels liés à une augmentation du risque de lésion hépatique chez les patients adultes ayant précédemment participé aux essais cliniques du tolvaptan dans le traitement de la polykystose rénale autosomique dominante (PKRAD)

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.


title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy

lead_sponsor: Biotec Pharmacon ASA


title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs

acronym: HDL functionality

lead_sponsor: F. HOFFMANN-LA ROCHE LTD


title: A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the treatment of Post-Operative Ileus (POI)

lead_sponsor: Progenics Pharmaceuticals, Inc.


title: A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, phase III trial.

lead_sponsor: TRB CHEMEDICA INTERNATIONAL SA


title: A randomised, double-blind, placebo-controlled study to assess the safety and activity of pentosan polysulfate sodium on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain in patients with sickle cell disease

acronym: A Study of PPS in Sickle Cell Disease

lead_sponsor: TRF Pharma, Inc.


title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Two-arm Safety and Efficacy Study of SYN118 as Adjunctive Therapy in Subjects with Parkinson‟s Disease

lead_sponsor: Synosia Therapeutics AG


title: Evaluation de l’efficacité de l’association ibuprofène et codéine versus l’ibuprofène seul dans le traitement de la poussée douloureuse de la gonarthrose. Etude en double aveugle, randomisée contrôlée de 2 groupes parallèles de patients traités pendant 7 jours.

acronym: EVACOD

lead_sponsor: Laboratoires ELERTE


title:
Genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

 Etude d’allocation génétique de la prophylaxie antifongique chez les patients traités pour une leucémie aiguë myéloïde

acronym:
PTX3-AML

 PTX3-AML

lead_sponsor: Centre Hospitalier Universitaire Vaudois


title: Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) with a documented upper respiratory tract infection (URTI) with respiratory syncytial virus (RSV)

lead_sponsor: ReViral Ltd.


title: Cure COVID: A prospective, controlled, randomized study to compare the efficacy of GNS561 versus standard of care in patients with SARS-CoV-2 (COVID-19) infection.

lead_sponsor: Genoscience Pharma


title: Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial

lead_sponsor: Astion Pharma A/S


title: Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)

lead_sponsor: NeuroVia, Inc.


title: A Multicenter, Three- arm, Double- blind, Double dummy, Parallel-group, placebo controlled Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily in comparison with conventional release formulation of Betahistine IR 24 mg, twice daily in treatment of adult patients with Menière's disease.

acronym: BERTIGO

lead_sponsor: INTAS PHARMACEUTICALS LIMITED


title:
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone

 DENOEUROSARC-007 - Etude de phase 2 multicentrique, en ouvert du denosumab chez des patients présentant des tumeurs osseuses riches en cellules géantes

acronym:
DENOEUROSARC-007

 DENOEUROSARC-007

lead_sponsor: Leiden University Medical Center


title: A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)

lead_sponsor: Transposon Therapeutics, Inc


title:
Comparison of the analgesic effect of a new paracetamol formulation (paracetamol UNIFLASH) for buccal use and two different doses of an oral paracetamol form controlled versus placebo in patients suffering from moderate pain due to a tooth extraction.

 Comparaison de l’effet analgésique d’une nouvelle formulation de paracétamol (paracétamol UNIFLASH) à usage buccal et de deux doses différentes d’une forme orale de paracétamol, contrôlée versus placebo, chez des patients souffrant de douleurs modérées dues à une extraction dentaire

acronym: PARAMOUTH

lead_sponsor: UNITHER Pharmaceuticals


title: A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TOEVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BFKB8488A COMPAREDWITH PLACEBO IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS.

lead_sponsor: Genentech Inc


title: Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have received radical surgery. A European Association of Urology Research Foundation Phase II Clinical Trial

acronym: Adjuvant Pemigatinib in surgically treated high-risk UC

lead_sponsor: EAU Research Foundation


title:
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2

 Essai de phase III, multicentrique, randomisée, contrôlée en double aveugle, pour déterminer la sécurité et l’efficacité du Renexus® dans la Télangiectasie Maculaire de type 2

lead_sponsor: Neurotech Pharmaceuticals


title:
Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial

 Surveillance clinique versus anticoagulation chez les patients à faible risque souffrant d'embolie pulmonaire sous-segmentaire isolée : essai randomisé, multicentrique, de non-infériorités, contrôlé par placebo (SAFE-SSPE)

acronym: SAFE-SSPE

lead_sponsor: Bern University Hospital


title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies

lead_sponsor: OncoResponse, Inc.


title:
AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation

 AUDIOWOLF: Etude de phase II, en ouvert, visant à évaluer l'efficacité du valproate de sodium administré de façon quotidienne chez des patients cliniquement atteints par le syndrome de Wolfram dû à une mutation monogénique

acronym: AUDIOWOLF

lead_sponsor: CECS/I-Stem


title:
Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients  with advanced or metastatic solid tumors
 International, multicenter, open label study

lead_sponsor: PIERRE FABRE MEDICAMENT


title:
A Phase 3 Open-Label Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects with Arginase 1 Deficiency

 Étude de phase III en ouvert évaluant la sécurité de la pegzilarginase en administration sous-cutanée hebdomadaire chez des sujets présentant un déficit en arginase 1

lead_sponsor: Aeglea Biotherapeutics, Inc.


title: Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant, Epithelial Ovarian  Cancer (AVALON)

acronym: AVALON

lead_sponsor: Immunovaccine Technologies Inc. (IMV Inc.)


title: A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention with Adjuvant Nivolumab in Non- Small Cell Lung Cancer Participants with ctDNA detected Minimal Residual Disease after Surgical Resection

acronym: CheckMate 9TN

lead_sponsor: Bristol-Myers Squibb International Corporation


title:
A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

 Etude de phase II multicentrique non randomisée évaluant le traitement par BST-236 chez les patients présentant un syndrome myélodysplasique de haut risque ou une leucémie aiguë myéloïde réfractaire ou en rechute, non éligibles à la chimiothérapie intensive

acronym: GFM- BST003

lead_sponsor: Groupe Francophone des Myélodysplasies (GFM)


title: Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS)

acronym: RIBOLARIS

lead_sponsor: SOLTI


title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)

lead_sponsor: HANLIM PHARM CO., LTD


title: Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial

acronym: neo-checkray

lead_sponsor: Institut Jules Bordet


title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

lead_sponsor: Harpoon Therapeutics, Inc.


title:
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer

 Étude de phase 2 à deux cohortes portant sur FL-101 en traitement néoadjuvant chez des patients atteints d’un cancer bronchique non à petites cellules opérable

acronym: Phase 2 Study of FL-101 in NSCLC

lead_sponsor: Flame Biosciences


title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

acronym: SYNERGY trial


title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA

acronym: VALYM

lead_sponsor: LYSARC


title: Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

acronym: AURA

lead_sponsor: Insitut Jules Bordet


title: A randomized, double-blind, placebo-controlled, cross-over trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by functional magnetic resonance imaging (FMRI) of the brain

lead_sponsor: Aarhus University


title:
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis treated by R-CHOP

 Etude de phase Ib-II du tazemetostat (EPZ-6438) chez des patients
 atteints de lymphome diffus à grandes cellules B (DLBCL) de
 risque élevé traités par R-CHOP


title: An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed By an Open-Label Long-Term Extension

lead_sponsor: Pharming Technologies B.V.


title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma

lead_sponsor: Centre Oscar Lambret


title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular toxicity in cancer patients treated with SYD985.

lead_sponsor: Byondis B.V.


title: Efficacy of Oscillococcinum® in the treatment of Influenza-like-illness symptoms: a national, multicentre, randomized, controlled trial

acronym: GOSCI

lead_sponsor: BOIRON


title:
A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination

 Essai preuve de concept explorant la tolérabilité et l’efficacité d’une approche par trithérapie chez des patients atteints de cancer du poumon non à petites cellules (CPNPC) de stade avancé ou métastatique et permettant d’évaluer rétrospectivement un algorithme intégrant informations génomiques et transcriptomiques ayant pour objectif d’identifier les patients pouvant bénéficier de la trithérapie testée.

acronym: SPRING

lead_sponsor: Worldwide Innovative Network Association


title:
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers

 Étude de phase II en ouvert évaluant ADP-A2M4CD8 chez des patients atteints de cancers avancés de l’œsophage ou de la jonction œsogastrique

acronym: SURPASS-2 study

lead_sponsor: Adaptimmune LLC


title:
Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemia

 Évaluation de la l'efficacité, du délai d'action, et de la tolérance de Tot'héma® chez l'adulte présentant une anémie modérée ferriprive

acronym: FAST

lead_sponsor: Laboratoire Innotech Internationnal


title: A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson’s disease

lead_sponsor: Integrative Research Laboratories Sweden AB (IRLAB)


title: SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction

lead_sponsor: Charité Universitätsmedizin Berlin


title: A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension

acronym: IIH EVOLVE

lead_sponsor: Invex Therapeutics Ltd.


title: Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial

acronym: MIME-A


title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer

acronym: BINGO

lead_sponsor: Institut Gustave Roussy


title:
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

 Étude de phase 2 à double cohorte, en ouvert portant sur le brentuximab védotine et le CHP (A+CHP) dans le traitement de première ligne de patients atteints de lymphome à cellules T périphérique (LCTP) avec moins de 10 % d’expression de CD30

lead_sponsor: Seattle Genetics, Inc.

status: Trial now transitioned


title: A dose escalation and phase IIa study of TG6002 plus flucytosine in patients with unresectable colorectal cancer with liver metastases

lead_sponsor: TRANSGENE S.A.


title:
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

 Essai clinique en ouvert, à bras unique de phase II des lymphocytes T ADP-A2M4 SPEARTM chez des patients atteints de sarcome synovial avancé ou de liposarcome myxoïde/à cellules rondes (LSMCR)

acronym: SPEARHEAD 1 STUDY


title: Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care

acronym: VASE

lead_sponsor: Cliniques Universitaires Saint-Luc (CUSL)


title: In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX)

lead_sponsor: Wyeth Pharmaceuticals


title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitis

lead_sponsor: Stallergenes S.A.


title: An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients

lead_sponsor: MediGene AG


title: EFFICACY STUDY OF THE ANTIHISTAMINE V0114 CP 2.5MG TABLET IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS.  A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibrate 160mg/Pravastatin 40mg combination versus Simvastatin 20mg in patients without Cardiovascular disease (CVD) (group 1) and of Fenofibrate 160mg/Pravastatin 40mg combination+Ezetimibe 10mg versus Simvastatin 20mg+Ezetimibe 10mg in patients with CVD (group 2), followed by a 12-week safety phase of  Fenofibrate 160mg/Pravastatin 40mg combination in group 1 and of Fenofibrate 160mg/Pravastatin 40 mg combination+Ezetimibe 10mg in group 2.

acronym: PREFED "PRavastatin, Ezetimibe and FEnofibrate in Diabetic patients"

lead_sponsor: Laboratoires SMB S.A.


title: A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma

acronym: FEDEGYN 01/0902  - PORTEC 3

lead_sponsor: Leiden University Medical Centre


title: A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

lead_sponsor: Novartis Pharma Service AG


title: A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell Lung Cancer who Have Failed One Prior Platinum-based Chemotherapy Regimen.

lead_sponsor: AstraZeneca AB


title: A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)

lead_sponsor: BTG International Ltd


title: Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.

lead_sponsor: ASSOCIAZIONE QOL-ONE


title: A phase II study of CP-4126 in patients with advanced pancreatic cancer

lead_sponsor: Clavis Pharma ASA


title: Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anemia

lead_sponsor: Schering-Plough Research Institution, A Division of Schering Corporation


title: An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106

acronym: Not applicable.

lead_sponsor: Novartis Pharma Services AG


title: Non inferiority study of a malathion 0.5% lotion versus reference therapy in the treatment of head lice: multicentre, randomised, investigator masked, parallel group.

lead_sponsor: Pierre Fabre Dermo-Cosmétique


title:
A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency

 Etude de Phase II, multicentrique, randomisée, en ouvert, de doses répétées, de comparaison de doses, visant à évaluer la tolérance, l’efficacité et la pharmacocinétique de la sphingomyelinase acide humaine recombinante chez des patients avec un déficit en sphingomyelinase acide

lead_sponsor: Genzyme Corporation


title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants

lead_sponsor: Fresenius Kabi Deutschland GmbH


title: An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients

acronym: Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

lead_sponsor: Alcon Research Ltd


title: A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in patients with Prader-Willi Syndrome

lead_sponsor: Alize Pharma


title:
A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors

 Etude Clinique de phase I/II, multicentrique et en ouvert, évaluant l'administration intratumorale/lésionnelle de RGT100 chez des patients atteints de tumeurs avancées ou récidivantes.

acronym: A Phase I/II trial of intralesional administration of RGT100

lead_sponsor: Rigontec GmbH


title: A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutations

lead_sponsor: Array BioPharma Inc.


title:
AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS)

 ÉTUDE EXPLORATOIRE OUVERTE ÉVALUANT L’UCB5857 CHEZ DES PATIENTS PRÉSENTANT UN SYNDROME DE PHOSPHO-INOSITIDE-3-KINASE (PI3K) DELTA ACTIVÉE (SYNDROME APDS)

lead_sponsor: UCB Celltech, UK Registered Branch of UCB Pharma SA


title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER

lead_sponsor: Vanda Pharmaceuitcals Inc.


title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) – (KEYNOTE-086)

acronym: A Phase II Study of Pembrolizumab in Subjects with Triple-Negative Breast Cancer

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.

lead_sponsor: Theratechnologies Inc.


title: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)

acronym: CYSIF

lead_sponsor: GETAID


title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age

lead_sponsor: Sanofi Pasteur MSD SNC